The University of Texas MD Anderson Cancer Center, Houston, TX
Funda Meric-Bernstam , Michael Rothe , Elizabeth Garrett-Mayer , Rodolfo Gutierrez , Eugene R Ahn , Timothy Lewis Cannon , Steven Francis Powell , John C. Krauss , Christopher M. Reynolds , Margaret von Mehren , Deepti Behl , Carmen Julia Calfa , Herbert Leon Duvivier , Henry G. Kaplan , Michael B. Livingston , Manish Sharma , Walter John Urba , Raegan O'Lone , Richard L. Schilsky , Susan Halabi
Background: TAPUR is a phase II basket study evaluating anti-tumor activity of commercially available targeted agents in pts with advanced cancers with genomic alterations. Results in a cohort of pts with solid tumors with BRAF V600E/D/K/R mutation (mut) treated with C+V are reported. Methods: Eligible pts had advanced solid tumors, no standard treatment (tx) options, measurable disease, ECOG performance status (PS) 0-2, and adequate organ function. Genomic testing was performed in CLIA-certified, CAP-accredited site selected labs. Pts matched to C+V had various solid tumors with BRAF V600E/D/K/R mut, or other BRAF mut if approved by the Molecular Tumor Board, and no MAP2K1/2, MEK1/2, NRAS mut. Recommended dosing was C, 60 mg orally daily for 21 days, 7 days off and V, 960 mg orally every 12 hours. Primary endpoint was disease control (DC), defined as complete (CR) or partial (PR) response or stable disease at 16+ wks (SD 16+) (RECIST v1.1). Low accruing histology-specific cohorts with the same genomic target and tx were collapsed into a single histology-pooled cohort for this analysis. For histology-pooled cohorts with sample size of 28, the results are evaluated based on a one-sided exact binomial test with a null DC rate of 15% vs. 35% (power = 0.84; α = 0.10) and one-sided 90% confidence interval (CI). Other efficacy endpoint estimates are presented with two-sided 95% CIs. Secondary endpoints were progression-free survival (PFS), overall survival (OS) and safety. Results: 31pts with solid tumors (13 histologies; 6/31 ovarian cancer) with BRAF muts were enrolled from Dec 2016 to Jan 2021 and collapsed into one histology pooled cohort for analysis. 3 pts were not evaluable due to lack of post-baseline tumor evaluation and excluded from efficacy analyses. Demographics and outcomes are summarized in the Table. Pts had tumors with BRAF V600E mut (N = 26), G469V mut (N = 1), K601E mut (N = 2), N581I (N = 1) and T599_V600insT (N = 1). 2 CR (breast and ovarian cancer; V600E), 14 PR (13 V600E, 1 N581I), and 3 SD16+ (2 V600E, 1 T599_V600insT) were observed for a DC rate of 68% (90% CI: 54%, 100%) and an objective response (OR) rate of 57% (95% CI: 37%, 76%). CR durations were 5.1 (ovarian cancer) and 108.9 wks (breast cancer) and median duration of PR was 20.5 wks (range: 8.0, 176.0). 19 pts experienced ≥1 Grade 1-5 AE/SAE at least possibly related to tx including 1 death attributed to tx-related kidney injury. Conclusions:C+Vdemonstrated evidence of anti-tumor activity in pts with advanced solid tumors with BRAF V600E and other muts.Clinical trial information: NCT02693535.
Median age, yrs (range) | 63 (31, 79) | |
ECOG PS, % | 0 | 23 |
1 | 64 | |
2 | 13 | |
Prior systemic regimens, % | 0-2 ≥3 | 48 52 |
DC rate, % (OR or SD16+) (90% CI) | 68 (54, 100) | |
OR rate, % (95% CI) | 57 (37, 76) | |
Median PFS, wks (95% CI) | 23.3 (13.3, 27.7) | |
Median OS, wks (95% CI) | 60.9 (26.7, 116.3) |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: Guglielmo Vetere
2020 Gastrointestinal Cancers Symposium
First Author: Kelsey Klute
2022 ASCO Annual Meeting
First Author: Gordan Srkalovic
2023 ASCO Annual Meeting
First Author: Carmen Julia Calfa